



Venture Capital

2009-2010: Emerging companies and leading venture capitalists throughout the United States and Europe turn to WilmerHale for legal advice and business advantage. Hundreds of start-up companies have relied on us from formation to funding to market leadership and successful IPOs or acquisitions. In 2009, we served as counsel in more than 250 venture financings raising over \$1.75 billion, including some of the largest and most prominent deals of the year. Since 2000, we have handled more than 2,000 venture financings raising over \$20 billion. With one of the top venture capital practices in the world, we are counsel to more venture capital-backed companies in the eastern half of the United States, and in Europe, than any other law firm.

Counsel of Choice for Venture Capital Financings

SERVING INDUSTRY LEADERS IN TECHNOLOGY, LIFE SCIENCES, CLEANTECH, FINANCIAL SERVICES, COMMUNICATIONS AND BEYOND

 <p>A123 SYSTEMS</p> <p>\$100,000,000 Late Stage April 2009</p>	 <p>ON-Q-ITY</p> <p>\$26,000,000 First Round October 2009</p>	 <p>catabasis</p> <p>\$40,000,000 First Round April 2010</p>	 <p>Gloucester PHARMACEUTICALS</p> <p>\$29,000,000 Fourth Round August 2009</p>	 <p>VIRDANTE PHARMACEUTICALS</p> <p>\$47,750,000 First Round October 2009</p>	 <p>OPHTHOTECH</p> <p>\$30,000,000 Second Round December 2009</p>	 <p>cöpanion.</p> <p>\$10,200,000 Second Round October 2009</p>	
 <p>TETRAPHASE PHARMACEUTICALS</p> <p>\$10,000,000 Second Round September 2009</p>	 <p>BioVex advanced vaccines</p> <p>\$70,000,000 Late Stage November 2009</p>	 <p>ALNARA PHARMACEUTICALS</p> <p>\$35,000,000 Second Round January 2010</p>	 <p>CERULEAN LEADERSHIP IN NEW PHARMACEUTICALS</p> <p>\$10,000,000 Second Round July 2009</p>	 <p>tōkai pharmaceuticals</p> <p>\$22,000,000 Third Round May 2009</p>	 <p>PETRA SOLAR</p> <p>\$40,000,000 Second Round January 2010</p>	 <p>OXAGEN</p> <p>£16,000,000 Third Round November 2009</p>	 <p>nasuni</p> <p>\$7,000,000 First Round March 2009</p>
 <p>SEED</p> <p>\$8,600,000 Third Round August 2009</p>	 <p>VERACODE</p> <p>\$12,000,000 Fourth Round January 2010</p>	 <p>VERIVUE</p> <p>\$20,000,000 Third Round August 2009</p>	 <p>Xanodyne pharmaceuticals, Inc.</p> <p>\$88,000,000 Late Stage May and October 2009</p>	 <p>HEARTLAND ROBOTICS</p> <p>\$7,000,000 Second Round August 2009</p>	 <p>NOVOMER</p> <p>\$14,000,000 Second Round August 2009</p>	 <p>demandware eCommerce Freedom</p> <p>\$15,000,000 Fourth Round April 2009</p>	
 <p>Surface Logix</p> <p>\$15,000,000 Late Stage January 2009</p>	 <p>SPACECLAIM CORPORATION</p> <p>\$7,000,000 Third Round March 2009</p>	 <p>AILERON THE BARRETTES</p> <p>\$40,000,000 Fourth Round May 2009</p>	 <p>kolltan Pharmaceuticals, Inc.</p> <p>\$10,000,000 Second Round December 2009</p>	 <p>CambridgeSoft www.cambridgesoft.com</p> <p>\$31,300,000 Late Stage November 2009</p>	 <p>arsenal medical</p> <p>\$12,200,000 Second Round April 2009</p>		



Mixed Sources
 Product group from well-managed forests, controlled sources and recycled wood or fiber
 www.fsc.org Cert no. BV-COC-070904
 © 1996 Forest Stewardship Council

WilmerHale recognizes its corporate responsibility to environmental stewardship.



wilmerhale.com

Wilmer Cutler Pickering Hale and Dorr LLP is a Delaware limited liability partnership. Our United Kingdom offices are operated under a separate Delaware limited liability partnership of solicitors and registered foreign lawyers regulated by the Solicitors Regulation Authority (SRA No. 287488). In Beijing, we are registered to operate as a Foreign Law Firm Representative Office. WilmerHale principal law offices: 60 State Street, Boston, Massachusetts 02109, +1 617 526 6000; 1875 Pennsylvania Avenue, NW, Washington, DC 20006, +1 202 663 6000. This material is for general informational purposes only and does not represent our legal advice as to any particular set of facts; nor does it represent any undertaking to keep recipients advised of all relevant legal developments. Prior results do not guarantee a similar outcome. © 2010 Wilmer Cutler Pickering Hale and Dorr LLP